Introduction: Sarcoidosis is an inflammatory disease characterized by non-caseating granulomas that can be present in diverse organ systems. Sarcoidosis can be associated with malignancy, presenting either preceding, during, or after chemotherapy. We herewith report a case of sarcoidosis mimicking cancer recurrence that developed after radioactive iodine therapy for papillary thyroid cancer.
Background: A 68-year-old Caucasian woman was found to have an incidental mediastinal lymph node. She underwent biopsy, which revealed sarcoidosis. There was no further treatment or evidence of recurrence over the ensuing 9 years. She was then diagnosed with low-grade papillary thyroid cancer in the right posterior lobe and treated with total thyroidectomy followed by radioactive iodine therapy. Six months later, she was found to have elevated serum thyroglobulin. Post-remnant ablation scan showed increased tracer uptake in the bed of the thyroid. Though two thyroid ultrasound scans were negative, she was treated with I-131 for possible recurrence. She then developed right hip pain, prompting further investigation. Though a skeletal survey was negative, an 18-fluorodeoxyglucose positron emission tomography (PET) scan study revealed multiple hypermetabolic skeletal lesions in both humeri and the proximal left femur. In addition, hypermetabolic hilar and mediastinal nodes were noted. As widespread cancer metastasis was suspected, bone biopsy was performed, which showed non-caseating granulomas, consistent with recurrence of sarcoidosis.
Conclusion: Sarcoid lesions may mimic metastatic disease or recurrence in oncologic patients. Biopsy and histopathology examination should be performed to confirm the diagnosis. Recurrence or reactivation of sarcoidosis has been proposed to result from altered immunologic milieu because of the presence of either active cancer or its therapy. Teodorovic and colleagues postulated that the radioactive I-131 therapy leads to reduced secretion of Th2 cytokines such as interleukin (IL)-4, IL-5, and IL-13. Few case reports of sarcoidosis associated with papillary carcinoma have been published; this is the first report of systemic recurrence of sarcoidosis associated with papillary thyroid carcinoma after treatment with radioactive iodine therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318835 | PMC |
http://dx.doi.org/10.3402/jchimp.v5.26360 | DOI Listing |
Environ Pollut
January 2025
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China; Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address:
Differentiated thyroid cancer (DTC) generally has a favorable prognosis, and radioactive iodine (RAI) therapy is typically used for metastatic DTC that continues to progress and poses life-threatening risks. However, resistance to RAI in metastatic DTC significantly impairs treatment effectiveness. This study aims to identify potential compounds that may influence RAI efficacy.
View Article and Find Full Text PDFCureus
December 2024
Department of Midwifery, School of Health and Care Sciences, University of West Attica, Athens, GRC.
Maternal Graves' disease (GD) poses a significant risk to neonatal thyroid function due to the transplacental transfer of thyrotropin receptor antibodies (TRAbs). This systematic review aims to assess the impact of maternal GD on neonatal thyroid outcomes and identify key maternal factors influencing these outcomes. A comprehensive literature search was conducted across PubMed, Scopus, and Cochrane, resulting in the inclusion of 18 studies published from 2014 to 2024.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Introduction: Radioactive iodine (RAI) is commonly used in the management of differentiated thyroid cancers (DTCs). However, the long-term efficacy and the risk of tumor recurrence associated with it remain unclear. In particular, the comparison between recombinant human thyrotropin (rhTSH) and thyroid hormone withdrawal (THW) in terms of medium- and long-term recurrence rate in DTC patients has not been fully elucidated.
View Article and Find Full Text PDFBioorg Med Chem
December 2024
Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, United States. Electronic address:
The purinergic P2X ligand-gated ion channel 7 receptor (P2X7R) plays a critical role in various inflammatory processes and other diseases. Fast determination of compounds P2X7R binding potency and discovery of a promise PET radiotracer for imaging P2X7R require a P2X7R suitable radioligand for radioactive competitive binding assay. Herein, we designed and synthesized thirteen new P2X7R ligands and determined the in vitro binding potency.
View Article and Find Full Text PDFInt J Comput Assist Radiol Surg
December 2024
Graduate School of Science and Technology, Hirosaki University, Hirosaki, Japan.
Purpose: We are developing a three-dimensional X-ray fluorescence computed tomography (3D XFCT) system using non-radioactive-labeled compounds for preclinical studies as a new modality that provides images of biological functions. Improvements in image quality and detection limits are required for the in vivo imaging. The aim of this study was to improve the quality of XFCT images by applying a deep image prior (DIP), which is a type of convolutional neural network, to projection images as a pre-denoising method, and then compare with DIP post-denoising.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!